Welcome to our dedicated page for Avalon Globocare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon Globocare stock.
Avalon GloboCare Corp. reports developments across precision diagnostic consumer products, generative AI publishing and software, and related intellectual property. The company markets the KetoAir breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device, and it has described plans to extend breathalyzer technology into additional diagnostic uses.
Recurring company updates also cover Avalon Quantum AI LLC, the Catch-Up generative and agentic AI video platform, provisional patent filings for automated commentary systems, and technology collaborations supporting AI media infrastructure. Avalon news also includes capital-structure actions such as private placements, warrant issuances, debenture conversions, shareholder approvals, and Nasdaq compliance matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Avalon GloboCare Corp. (NASDAQ: ALBT) announced that Laboratory Services MSO, (LSM), in which Avalon owns a 40% interest, has acquired DE Laboratory (DE Labs) in Houston, Texas. This acquisition expands LSM's presence in Texas and offers significant growth potential. DE Labs is a CLIA-certified and COLA-accredited laboratory that performs about 1,500 lab tests per month, focusing on toxicology and wellness testing.
LSM will operate DE Labs as a fully owned subsidiary and has invested capital for geographical expansion into surrounding counties. The acquisition aligns with Avalon's strategy to expand LSM through acquisitions and strategic relationships in the fragmented laboratory testing market. Avalon aims to target laboratories with exceptional performance, positive revenue track records, and niche-market advantages.
Summary not available.
Summary not available.
Avalon GloboCare Corp. (NASDAQ: ALBT) announced a substantial future cash flow expectation due to a 40% profit-sharing agreement with Laboratory Services MSO (LSM). In 2022, LSM reported significant financials: $14.7 million in revenue, $8.1 million gross profit, $2.4 million in operating expenses, and a net income of $6.3 million. Avalon acquired a 40% interest in LSM in February 2023, which enhances its strategic position in the laboratory services market. The company's growth strategy focuses on leveraging LSM's expertise in the fragmented laboratory testing space and aims to generate synergies through targeted acquisitions. Avalon also highlights LSM's strong customer service reputation, rapid turnaround times, and diverse test offerings as key competitive advantages.
Avalon GloboCare Corp. (NASDAQ: ALBT) announced the commercial launch of the KetoAir™ breathalyzer at the KetoCon Austin 2023 conference, held from April 21-23, 2023. The KetoAir™ device, which is registered with the FDA, functions as a companion diagnostic and monitoring tool for ketogenic dietary management, combining AI nutritionist consultations. Avalon has partnered with Qi Diagnostics for exclusive distribution in North America, South America, the U.K., and the EU. The initial target markets include diabetes reversal and obesity management due to the efficacy of the ketogenic diet. KetoAir™ is touted as the first breathalyzer of its kind that uses AI and a nanosensor for monitoring keto health, allowing users to track their dietary plans and receive personalized recommendations via the KetoAir app.
Avalon GloboCare Corp. (NASDAQ: ALBT) recently announced an agreement with Qi Diagnostics for exclusive distribution rights to the KetoAir™ breathalyzer in North America, South America, the U.K., and the EU. This device is aimed at the diabetes reversal and weight management markets, and combines AI nutritionist consultations with a nanosensor-based breathalyzer to monitor ketogenic dietary management. The FDA has approved KetoAir™, and Avalon plans to commercialize the product, which is backed by clinical evidence supporting nutritional ketosis for diabetes treatment. Additionally, both companies will collaborate on a lung cancer breathalyzer, sharing ownership of any resulting intellectual property. While the initial agreement is promising, a definitive agreement regarding terms and pricing is still pending.